Skip to content

Long-time efficacy of TEVAR and conservative treatment for acute Stanford B aortic dissection

Long-time efficacy of TEVAR and conservative treatment for acute Stanford B aortic dissection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16008857
Enrollment
Unknown
Registered
2016-07-19
Start date
2016-07-18
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stanford B aortic dissection

Interventions

TEVAR:endovascular repair
Conservative :medication

Sponsors

The First Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. acute Stanford B aortic dissection; 2. aged between 18 to 80 yrs, male and female; 3. Be able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patient will be younger than 18 years of age, or more than or equal to 80 years; 2. intramural hematoma and penetrating ulcer are excluded. 3. Patient with current medical condition with a life expectancy less than 3 months; 4. The patient had sympomatic myoinfarction within 3 months or uncontrollable heart failure; 5. The patient had severe respiratory failure (PO250 mmHg); 6. The patient had renal failure with creatine level more than 200 umol/L; 7. The patient had severe liver disfunction.

Design outcomes

Primary

MeasureTime frame
all-cause mortality;Aortic related mortality;

Secondary

MeasureTime frame
rupture;Malperfusion;

Countries

China

Contacts

Public ContactShijie Xin

The First Hospital of China Medical University

wenhaocmu@163.com+86 15241790086

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026